RecruitingPhase 3NCT05066217
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Studying Lennox-Gastaut syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Epygenix
- Principal Investigator
- Amit Ray, MDHarmony Biosciences Management, Inc.
- Intervention
- Clemizole HCl(drug)
- Enrollment
- 260 enrolled
- Eligibility
- 2-55 years · All sexes
- Timeline
- 2025 – 2026
Study locations (4)
- Rare Disease Research, Kissimmee, Florida, United States
- Minnesota Epilepsy Group, P.A., Roseville, Minnesota, United States
- Neurology Center for Epilepsy and Seizures, Marlboro, New Jersey, United States
- On-Site Clinical Solution, Charlotte, North Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05066217 on ClinicalTrials.govOther trials for Lennox-Gastaut syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06924086The Children's Adaptive Deep Brain Stimulation for Epilepsy TrialUniversity College, London
- RECRUITINGNCT05485831Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALYJazz Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT06464653Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut SyndromeLiankun_Ren
- RECRUITINGNCT05374824Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut SyndromeAnn & Robert H Lurie Children's Hospital of Chicago
- ACTIVE NOT RECRUITINGPHASE4NCT05044819Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionJazz Pharmaceuticals